AngioDynamics Launches Total Abscession ® Nephrostomy Drainage Catheter
QUEENSBURY, N.Y., Dec 29, 2009 (BUSINESS WIRE) -- AngioDynamics (NASDAQ:ANGO) announced today the release of its new Total Abscession nephrostomy drainage catheter. The launch of this product completes the Total Abscession family of products - including general drains and a biliary drainage catheter - giving physicians and hospitals a full range of choice from one source.
The new drain is used in percutaneous nephrostomy drainage, a minimally invasive procedure in which a physician places this catheter through the skin in the back into the kidney to relieve pressure on the kidney from a back-up of urine.
The Total Abscession nephrostomy drain has six side holes and a tight curl at the distal end of the catheter to ensure the drain tip lies completely inside of the pigtail shape, avoiding irritation of the renal pelvis.
"The Total Abscession nephrostomy drain is not only designed to be a leading product in its category, it establishes AngioDynamics as a one-stop provider of drainage catheters in addition to all of the other leading products physicians rely on us to deliver," said Shawn McCarthy, Senior Vice President and General Manager of the Peripheral Vascular business unit. "The focus on security, physician performance and patient comfort displayed in this latest introduction highlights our ongoing commitment to quality as the cadence of new products continues from AngioDynamics."
The Vault(R) locking mechanism featured on the Total Abscession drain prevents tampering or accidental removal and an audible click provides confirmation the lock is engaged. A thermal molded tip is designed for less buckling and kinking upon insertion and a Blue Silk(TM) finish provides easier insertion and pushability, increasing physician performance. The low-profile hub and soft, pliable strain relief provide optimal patient comfort regardless of the anatomical access point.
For more information on Total Abscession drainage catheters, visit the AngioDynamics web site at www.angiodynamics.com.
AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "potential," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
SOURCE: AngioDynamics, Inc.
D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608
EVC Group, Inc.
Doug Sherk or Jenifer Kirtland, 415-896-2005
Chris Gale or Steve DiMattia, 646-201-5431
Copyright Business Wire 2009